Abstract
' The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012' is a new
report from visiongain providing analysis of the current and future market for
IBD drugs across all major indications. Forecasts are given based on new
product launches, upcoming patent expiry dates, and ongoing clinical trials to
enable you to predict changes in the dynamics of the global IBD market.
Autoimmune disease is a multimillion dollar market set to increase as world
prevalence rates rise and the population lives longer. Inflammatory bowel
disease (IBD) affect millions of people worldwide with 2.8 million currently
diagnosed with ulcerative colitis (UC) or Crohn' s disease (CD) in the US
alone. The incidence of IBD is rising in developing countries around the
world. Currently the global market is estimated at $16bn and this is set to
continue to rise.
Historically, management of IBD with sulphonamides and corticosteroids did
little to alter the course of disease and had severe side effects. In the
1990' s new therapies were introduced in the form of enteric coated
aminosalicylates (5-ASA). From 3 drugs and one target in 1993 there are now
more than 30 products and 10 targets. With the advent of monoclonal antibodies
for use in IBD there has been a breakthrough in disease management which is
set to expand rapidly over the next few years. Many more expensive biologicals
are in the pipeline. As they gain approval and are prescribed in favour of
cheaper options, revenues in the IBD market will grow rapidly.
- Will the current monoclonal blockbuster used to treat IBD continue to grow?
- What are the hottest research drugs in the pipeline?
- Will safety of issues restrict the use of biological agents in IBD?
Buy this report to find out!
Included in this report:
This report includes an up-to-date, analysis of IBD including the current
market and possible future developments. The following important issues are
covered in detail:
What new anti-inflammatory drugs are seeking the IBD indication Unique
analysed forecast for the biologicals market for IBD, 2007-2012 Summaries and
revenue forecasts for the leading 5-ASA drugs, 2007-2012 Summaries and
revenue for monoclonal antibody drugs, 2007-2012 A thorough examination of
the biological pipeline for IBD including cytokine, chemokine and adhesion
molecule antagonists An assessment of future developments You must order this
report today.
Unique benefits to you when you order this report:
- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using
harddrive space
- Primary research throughout. You will not find this information anywhere
else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
If you buy one report this year make sure it is the report that will guarantee
your success for the forthcoming years. Order this report now.
View Cart
